<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539630</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976F_3501</org_study_id>
    <nct_id>NCT00539630</nct_id>
  </id_info>
  <brief_title>TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To describe the clinical response rate in two groups (Docetaxel plus cisplatin plus 5-FU,
      versus Cisplatin plus 5-FU) after 3 cycle of neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response will be evaluated by modified WHO criteria. Clinical and radiological assessment of all lesions will be performed</measure>
    <time_frame>After 2 cycle, 3 cycle and after concurrent chemo/radiotherapy.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic response if clinical response of primary tumor is CR at the end of chemotherapy and end of concurrent chemo/ radiotherapy, biopsy of primary tumor site will be performed to evaluate pathologic response rate.</measure>
  </secondary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven squamous cell carcinoma of the head and neck
             with locally advanced inoperable disease.

          -  Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx , larynx or
             nasopharynx.

          -  Patients are required to have at least one (bi-or uni-dimensionally) measurable
             lesion.

          -  WHO performance status 0 or 1.

          -  Adequate bone marrow, hepatic and renal functions.

        Exclusion Criteria:

          -  Pregnant and lactating women

          -  Previous chemotherapy

          -  Previous radiotherapy for H&amp;N

          -  Previous surgery for H&amp;N

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyang Rim Kim</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <last_update_submitted>October 3, 2007</last_update_submitted>
  <last_update_submitted_qc>October 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

